Clinical Commander

Back to dossier
id.bacterial-meningitis.peds.v1PRODUCTION
id.bacterial-meningitis.peds.v1

Pediatric bacterial meningitis

pediatricsacutepediatric
Hard-required inputs
0 / 22
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Pediatric bacterial meningitis pathway by age tier (<1 mo, 1-23 mo, ≥2 yr); rule out aseptic / viral / TB / fungal / CSF shunt infection

Inputs
1
Actions
0
Advance rule
Set
Advance when

Pediatric meningitis suspicion confirmed

Patient inputs (28)

Age tier defines organism risk and empiric antibiotic + dexamethasone decision (IDSA 2004 Tunkel)

All antibiotic / steroid / vasopressor dosing is weight-based (AAP 2021)

Fever pattern; hypothermia in young infants is concerning (NICE 2024 meningitis)

Septic shock overlap — age-based hypotension (AAP 2021)

Tachycardia / bradycardia + Cushing triad for raised ICP (IDSA 2004 Tunkel)

Respiratory irregularity = brainstem involvement (IDSA 2004)

Hib / pneumococcal / meningococcal coverage gaps drive empiric breadth (AAP 2021)

Pretreatment lowers culture yield; informs duration (IDSA 2004)

Asplenia, sickle cell, HIV, complement deficiency — recurrent meningococcal / pneumococcal risk (IDSA 2004 Tunkel)

Anticoagulation, prior abx, allergies (IDSA 2004)

CBC + diff; bandemia + leukopenia in severe sepsis (AAP 2021)

Serum glucose paired with CSF glucose for ratio (IDSA 2004 Tunkel)

Drug dosing (vancomycin, aminoglycoside) (IDSA 2004)

Coag screen + DIC marker; safe LP threshold (IDSA 2004)

Blood cultures x 1-2 before antibiotics if no delay (IDSA 2004 Tunkel)

WBC >=1000 (often neutrophil-predominant) suggests bacterial (IDSA 2004; Nigrovic 2007 BMS)

Bacterial usually >100 mg/dL (IDSA 2004 Tunkel)

CSF/serum ratio <0.4 suggests bacterial (IDSA 2004 Tunkel)

Definitive pathogen identification (IDSA 2004)

GCS deterioration / Glasgow Outcome marker; gates LP timing (CT first) (IDSA 2004 Tunkel)

Focal sign mandates CT before LP (IDSA 2004 Tunkel)

Recent seizure mandates CT before LP per IDSA 2004

Healthcare-associated organisms (Staph, gram-negative) (IDSA 2004)

Coagulopathy precludes LP (IDSA 2004)

Multiplex PCR (FilmArray ME) — rapid pathogen + viral discrimination (AAP 2021)

Raised ICP — defer LP; CT first; mannitol / hypertonic if herniation (IDSA 2004 Tunkel)

Petechial rash then meningococcaemia then time-critical antibiotics (NICE 2024 meningitis)

Before LP if focal deficit, AMS, papilledema, immunocompromise, recent seizure, signs of raised ICP (IDSA 2004 Tunkel)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (13)

13 need judgement
  • informationallife_threateningmeningococcaemia_features
    Petechial / purpuric rash with fever ± shock (suspected meningococcaemia)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningraised_icp_or_herniation_signs
    Cushing triad (HTN + bradycardia + irregular respirations), papilledema, fixed/dilated pupil, or rapid GCS decline
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningstatus_epilepticus_with_meningitis
    Continuous or recurrent seizure ≥5 min in a child with suspected meningitis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningseptic_shock_with_meningitis
    Hypotension / shock signs in pediatric meningitis
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpediatric_meningitis_with_hemodynamic_instability
    Pediatric bacterial meningitis + septic shock features (hypotension on age-adjusted thresholds + lactate ≥ 2 mmol/L + vasoactive requirement OR Phoenix cardiovascular sub-score ≥ 1; SSC peds 2020 Weiss PMID 32032273; Phoenix Schlapbach JAMA 2024 PMID 38245901) — most commonly Waterhouse-Friderichsen with meningococcus, but pneumococcal sepsis in immunocompromised host can present similarly
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpediatric_raised_icp_features
    Behaviourally explicit pediatric raised-ICP phenotype: fontanelle bulging in infant + bradycardia + HTN (Cushing reflex components) + abnormal / asymmetric pupils + GCS drop ≥ 2 points OR new posturing OR new seizure with elevated opening pressure OR paradoxical irritability in infant (IDSA 2004 Tunkel; ESCMID 2016; Glaser NEJM 2001 PMID 11172164 cerebral-edema risk-model analog)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsubdural_empyema_or_brain_abscess_features
    Focal neurologic deficit + persistent fever despite ≥ 48 h of appropriate empiric antibiotics OR new seizure or worsening AMS during treatment course → suspect subdural empyema, brain abscess, or ventriculitis (IDSA 2004 Tunkel; IDSA/AAN 2017 PMID 28203777; ESCMID 2016)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverect_indication_before_lp
    Focal neurological deficit, AMS, papilledema, immunocompromise, recent seizure, or signs of raised ICP
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereunvaccinated_for_hib
    Child <5 yr, incompletely vaccinated for Hib
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_meningitis
    Second episode in same patient
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredelayed_lp_or_abx_after_clinical_suspicion_peds
    Empiric dexamethasone + antibiotic NOT administered within ≤ 30-60 min of clinical suspicion of pediatric bacterial meningitis (≤ 30 min if suspected meningococcaemia per NICE NG240) OR LP delayed beyond 30 min when not contraindicated; ≥ 1 h mortality gradient stronger in peds per Kumar 2006 + Auburtin CCM 2006 PMID 16915106 + SSC peds 2020 Hour-1 bundle analog
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepediatric_bacterial_vs_viral_score_high_risk
    Nigrovic Bacterial Meningitis Score ≥ 1 (any of: positive CSF Gram stain OR CSF ANC ≥ 1000 cells/µL OR CSF protein ≥ 80 mg/dL OR peripheral ANC ≥ 10,000 cells/µL OR seizure at or before presentation) in alert child with CSF pleocytosis (Nigrovic JAMA 2007 PMID 17200475); high-risk → admit + empiric abx + LP-confirmed; BMS = 0 in alert child + reliable safety-net follow-up + viable viral aetiology (enterovirus PCR positive, summer epidemiology) = consider outpatient observation with 24-h re-check
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverehearing_loss_screening_required
    Pediatric bacterial meningitis admission requires audiology screening before discharge (admit-discharge process gate) — sensorineural hearing loss rates ~30% pneumococcal, ~10-20% Hib, ~5-10% meningococcal in peds survivors (Cochrane Brouwer 2010 PMID 20824838; AAP Red Book; NICE NG240 2024); discharge without audiology = process failure
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSoptionalDrives screening
Loading…

Recommended regimen

Pediatric bacterial meningitis empirics — age-tiered + dexamethasone for Hib
axis: peds_meningitis_empirics_by_agestep neonate_under_1_month - Neonate <1 mo — GBS, E. coli, Listeria
Selected step "Neonate <1 mo — GBS, E. coli, Listeria" — Age <1 mo with suspected bacterial meningitis
  • ampicillin
    first line
    aminopenicillin
    75 mg/kg/dose IV q6-8h (meningitis dose) • IV • q6-8h
    Listeria + GBS coverage (IDSA 2004 Tunkel)
    rxcui 733
  • cefotaxime
    first line
    cephalosporin_3rd
    50-75 mg/kg/dose IV q6-8h • IV • q6-8h
    Avoid ceftriaxone <1 mo (bilirubin / calcium-IVF concerns); cefotaxime preferred (IDSA 2004 Tunkel; AAP 2021)
    rxcui 2186
  • gentamicin
    add on
    aminoglycoside
    4-5 mg/kg/dose IV q24-36h (gestational age dependent) • IV • q24-36h
    triggers: synergy_for_listeria_or_gram_negative
    Synergy with ampicillin for Listeria; alternative if cefotaxime unavailable (IDSA 2004 Tunkel)
    rxcui 1596450
  • acyclovir
    add on
    antiviral
    20 mg/kg/dose IV q8h • IV • q8h
    triggers: HSV_risk, CSF_pleocytosis_with_lymphocytic_predominance, seizure_or_hepatitis_pattern
    Cover HSV until excluded; high mortality if missed (AAP 2021)
    rxcui 281

outpatient playbook — drug actions (8)

  1. 1. pneumococcal vaccine (PCV20)
    PCV20 0.5 mL IM × 1 (per ACIP 2024 simplified peds schedule; PCV15 then PPSV23 in 1 year if PCV20 unavailable; PCV13 if pre-PCV20 cohort) • IM • one dose (PCV20) per ACIP 2024
    trigger: Pneumococcal aetiology confirmed AND patient not previously vaccinated per current ACIP schedule
    ACIP 2024 simplified PCV20 peds schedule; meningitis survivors at increased risk of recurrent invasive pneumococcal disease
  2. 2. Hib vaccine
    0.5 mL IM per product (e.g., PedvaxHIB, ActHIB, Hiberix per age and series) • IM • one dose if not previously vaccinated AND age-appropriate
    trigger: Hib aetiology in incompletely vaccinated child OR functionally asplenic / complement deficient host
    AAP Red Book + ACIP — Hib catch-up after Hib meningitis; uncommon in fully vaccinated cohorts (Thigpen NEJM 2011)
  3. 3. meningococcal conjugate vaccine (MenACWY)
    0.5 mL IM per product (Menveo / MenQuadfi) • IM • two-dose primary if not previously vaccinated; booster per ACIP
    trigger: Meningococcal aetiology AND prior vaccination incomplete (ACIP)
    ACIP — meningitis survivors qualify as high-risk; protect against future serogroup-specific disease
  4. 4. meningococcal B vaccine (MenB-4C or MenB-FHbp)
    0.5 mL IM per product • IM • two-dose Bexsero OR three-dose Trumenba per ACIP
    trigger: Meningococcal serogroup B aetiology OR ongoing risk (functionally asplenic, complement deficiency, eculizumab/ravulizumab use)
    ACIP — serogroup B not covered by MenACWY; meningitis survivors are at risk for second serogroup
  5. 5. rifampin (chemoprophylaxis reinforcement)
    Meningococcal household + childcare contacts: 10 mg/kg PO q12h × 2 d (max 600 mg/dose); Hib contacts < 4 yr unvaccinated household: 20 mg/kg/day PO × 4 d (max 600 mg/day) • PO • q12h × 2 d (Nm) or daily × 4 d (Hib)
    trigger: Close-contact chemoprophylaxis verification at outpatient follow-up if not given in ED
    CDC + AAP Red Book — verify prophylaxis given; if not, prescribe and document compliance
  6. 6. ciprofloxacin (chemoprophylaxis adolescent alternative)
    20 mg/kg PO single dose (max 500 mg) — adolescent contacts only (AAP cautions fluoroquinolone in peds) • PO • single dose
    trigger: Adolescent meningococcal household contact unable to take rifampin
    CDC + AAP Red Book — single-dose alternative for adolescent contacts; avoid in younger peds unless no alternative
  7. 7. levetiracetam continuation / taper
    continue 20-40 mg/kg/day PO BID (typical maintenance); reassess at 3-6 months from last seizure • PO • BID
    trigger: Seizure at presentation during acute meningitis
    Bridge anticonvulsant prophylaxis; taper guided by peds-neurology + EEG; no high-grade evidence for fixed duration
  8. 8. restart pre-admission chronic regimen
    per patient baseline • per agent • per agent
    trigger: Stable post-discharge, no contraindication
    Avoid medication-list drift; reconcile any holds during shock — restart

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Fever + neck stiffness / photophobia / headache in a child; AMS / lethargy / irritability + fever in a child; Bulging fontanelle in an infant.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Pediatric bacterial meningitis** (id.bacterial-meningitis.peds.v1).
Phenotype framing: Bacterial vs viral (enterovirus, HSV, arboviral) vs TB vs fungal (cryptococcus in HIV) vs aseptic vs MIS-C / Kawasaki overlap with neuro features (IDSA 2004; AAP 2021)
Scope: Pediatric bacterial meningitis pathway by age tier (<1 mo, 1-23 mo, ≥2 yr); rule out aseptic / viral / TB / fungal / CSF shunt infection

No severity triggers fired against current inputs.

Plan

Regimen axis: **Pediatric bacterial meningitis empirics — age-tiered + dexamethasone for Hib** — step "Neonate <1 mo — GBS, E. coli, Listeria".
1. ampicillin 75 mg/kg/dose IV q6-8h (meningitis dose) IV q6-8h (aminopenicillin, first line) — Listeria + GBS coverage (IDSA 2004 Tunkel)
2. cefotaxime 50-75 mg/kg/dose IV q6-8h IV q6-8h (cephalosporin_3rd, first line) — Avoid ceftriaxone <1 mo (bilirubin / calcium-IVF concerns); cefotaxime preferred (IDSA 2004 Tunkel; AAP 2021)
3. gentamicin 4-5 mg/kg/dose IV q24-36h (gestational age dependent) IV q24-36h (aminoglycoside, add on) — Synergy with ampicillin for Listeria; alternative if cefotaxime unavailable (IDSA 2004 Tunkel)
4. acyclovir 20 mg/kg/dose IV q8h IV q8h (antiviral, add on) — Cover HSV until excluded; high mortality if missed (AAP 2021)

Setting playbook (outpatient) — Post-meningitis peds-ID + audiology + neurodev follow-up — peds-ID at 4-6 weeks; audiology at 4-6 weeks (sensorineural hearing loss ~30% pneumococcal, ~10-20% Hib, ~5-10% meningococcal in peds survivors per Cochrane Brouwer 2010 PMID 20824838 + AAP Red Book); neurodevelopmental assessment at 3 mo + 6 mo + annually with formal tools (Bayley III, Ages-and-Stages, Vineland for older); learning / school assessment; vaccination catch-up by causative organism (PCV20 if pneumococcal per ACIP 2024; Hib if Hib and not vaccinated; MenACWY + MenB if meningococcal); close-contact chemoprophylaxis reinforcement (rifampin or ciprofloxacin or single-dose ceftriaxone for meningococcal household contacts; rifampin for Hib contacts < 4 yr unvaccinated household per AAP Red Book + CDC); antiseizure medication taper plan if seizure at presentation; speech therapy if developmental regression; mental-health screen for child + caregivers (post-PICU PTSD / depression common); IDSA 2004 Tunkel + NICE NG240 (2024) + AAP Red Book + Cochrane Brouwer 2010
5. pneumococcal vaccine (PCV20) PCV20 0.5 mL IM × 1 (per ACIP 2024 simplified peds schedule; PCV15 then PPSV23 in 1 year if PCV20 unavailable; PCV13 if pre-PCV20 cohort) IM one dose (PCV20) per ACIP 2024 — Pneumococcal aetiology confirmed AND patient not previously vaccinated per current ACIP schedule (ACIP 2024 simplified PCV20 peds schedule; meningitis survivors at increased risk of recurrent invasive pneumococcal disease)
6. Hib vaccine 0.5 mL IM per product (e.g., PedvaxHIB, ActHIB, Hiberix per age and series) IM one dose if not previously vaccinated AND age-appropriate — Hib aetiology in incompletely vaccinated child OR functionally asplenic / complement deficient host (AAP Red Book + ACIP — Hib catch-up after Hib meningitis; uncommon in fully vaccinated cohorts (Thigpen NEJM 2011))
7. meningococcal conjugate vaccine (MenACWY) 0.5 mL IM per product (Menveo / MenQuadfi) IM two-dose primary if not previously vaccinated; booster per ACIP — Meningococcal aetiology AND prior vaccination incomplete (ACIP) (ACIP — meningitis survivors qualify as high-risk; protect against future serogroup-specific disease)
8. meningococcal B vaccine (MenB-4C or MenB-FHbp) 0.5 mL IM per product IM two-dose Bexsero OR three-dose Trumenba per ACIP — Meningococcal serogroup B aetiology OR ongoing risk (functionally asplenic, complement deficiency, eculizumab/ravulizumab use) (ACIP — serogroup B not covered by MenACWY; meningitis survivors are at risk for second serogroup)
9. rifampin (chemoprophylaxis reinforcement) Meningococcal household + childcare contacts: 10 mg/kg PO q12h × 2 d (max 600 mg/dose); Hib contacts < 4 yr unvaccinated household: 20 mg/kg/day PO × 4 d (max 600 mg/day) PO q12h × 2 d (Nm) or daily × 4 d (Hib) — Close-contact chemoprophylaxis verification at outpatient follow-up if not given in ED (CDC + AAP Red Book — verify prophylaxis given; if not, prescribe and document compliance)
10. ciprofloxacin (chemoprophylaxis adolescent alternative) 20 mg/kg PO single dose (max 500 mg) — adolescent contacts only (AAP cautions fluoroquinolone in peds) PO single dose — Adolescent meningococcal household contact unable to take rifampin (CDC + AAP Red Book — single-dose alternative for adolescent contacts; avoid in younger peds unless no alternative)
11. levetiracetam continuation / taper continue 20-40 mg/kg/day PO BID (typical maintenance); reassess at 3-6 months from last seizure PO BID — Seizure at presentation during acute meningitis (Bridge anticonvulsant prophylaxis; taper guided by peds-neurology + EEG; no high-grade evidence for fixed duration)
12. restart pre-admission chronic regimen per patient baseline per agent per agent — Stable post-discharge, no contraindication (Avoid medication-list drift; reconcile any holds during shock — restart)

Non-pharmacologic actions:
- Audiology referral within 4-6 weeks (NICE NG240 2024; Cochrane Brouwer 2010 PMID 20824838; AAP Red Book)
- ENT + hearing-aid / cochlear-implant evaluation if audiology demonstrates moderate-severe sensorineural hearing loss (Cochrane Brouwer 2010; AAP Red Book)
- Neurodevelopmental peds clinic referral at 3 months + 6 months + annually (AAP Red Book; van de Beek NEJM 2006 long-term sequelae framework)
- Speech therapy if developmental regression OR confirmed hearing loss (AAP Red Book; NICE NG240 2024)
- Physical / occupational therapy if functional decline from pre-illness baseline (ESCMID 2016)
- School / daycare 504 / IEP planning if cognitive or academic decline (AAP Red Book; NICE NG240 2024)
- Mental-health screening (PHQ-9-A age ≥ 12, UCLA-PTSD-RI younger, caregiver PHQ-9 / PSS-FH) — post-PICU PTSD and depression common in survivors (PICS-Family; SCCM PADIS 2018)
- Driving restrictions per local regulations if seizure occurred during admission and patient is age-eligible (NICE NG240 2024)
- Return-to-school / daycare guidance — typically full clearance once antibiotics completed + neurology stable + audiology booked (NICE NG240 2024)
- Public-health notification confirmation for meningococcal / Hib (AAP Red Book; CDC)
- Family + caregiver education on signs of recurrence, late-onset hydrocephalus, and seizure recurrence (IDSA 2004 Tunkel; ESCMID 2016)
- Caregiver support (PICS-Family) if extended PICU stay (SCCM PADIS 2018)

AVOID / contraindication checks:
- Ceftriaxone avoid under 1 month or with calcium IVF (IDSA 2004 Tunkel; AAP 2021)
- Dexamethasone only with or before first abx dose (Cochrane de Gans 2013)
- LP after CT if focal deficit AMS papilledema immunocompromise seizure (IDSA 2004 Tunkel)
- Do not delay antibiotics for LP more than 30 min (IDSA 2004; NICE 2024 meningitis)
- Fluoroquinolone avoid pediatric unless no alternative (AAP 2021)
- Vancomycin renal function q48h (IDSA 2004)

Monitoring

Regimen monitoring:
- neuro exam q1-4h initially (IDSA 2004; NICE 2024)
- electrolytes q12h for SIADH vs CSW (IDSA 2004 Tunkel)
- repeat LP at 24-48h if poor response or DRSP (IDSA 2004 Tunkel)
- audiology pre-discharge for Hib or pneumococcus (AAP 2021; NICE 2024 meningitis)
- vancomycin trough or AUC q48-72h (IDSA 2004)
- duration per organism Nm 5-7d Hib 7-10d Spn 10-14d Listeria 21d GBS 14-21d (IDSA 2004 Tunkel)

Setting (outpatient) monitoring:
- PCP / peds-ID visit within 1-2 weeks of discharge for clinical recheck (IDSA 2004 Tunkel; AAP Red Book)
- Audiology at 4-6 weeks (NICE NG240 2024)
- Peds-neurology follow-up at 4-6 weeks if any focal deficit / seizure (IDSA 2004 Tunkel)
- Neurodevelopmental assessment at 3 mo + 6 mo + annually using age-appropriate formal tools (AAP Red Book; van de Beek NEJM 2006)
- 30-day readmission monitoring — call family at day 7 and day 21 to triage symptoms (NICE NG240 2024)
- Vaccination completion tracking — schedule second-dose meningococcal series and 1-year PPSV23 if PCV15-route used (ACIP)
- School-performance + cognitive trajectory tracking annually through adolescence if any sequelae (AAP Red Book; NICE NG240 2024)

Follow-up plan: Audiology assessment (Hib / pneumococcus); neurodevelopmental review; outpatient ID f/u; immunisation catch-up + chemoprophylaxis for close contacts (rifampin / ciprofloxacin / ceftriaxone for Nm; rifampin for Hib if indicated)
- Close-out criterion: Follow-up + chemoprophylaxis arranged

Monitoring phase: Daily neuro exam, repeat LP at 24-48 h if poor response or DRSP-suspected, electrolytes (SIADH vs CSW), audiology pre-discharge, neurodevelopmental follow-up; vancomycin trough

Disposition

Current setting: outpatient — Post-meningitis peds-ID + audiology + neurodev follow-up — peds-ID at 4-6 weeks; audiology at 4-6 weeks (sensorineural hearing loss ~30% pneumococcal, ~10-20% Hib, ~5-10% meningococcal in peds survivors per Cochrane Brouwer 2010 PMID 20824838 + AAP Red Book); neurodevelopmental assessment at 3 mo + 6 mo + annually with formal tools (Bayley III, Ages-and-Stages, Vineland for older); learning / school assessment; vaccination catch-up by causative organism (PCV20 if pneumococcal per ACIP 2024; Hib if Hib and not vaccinated; MenACWY + MenB if meningococcal); close-contact chemoprophylaxis reinforcement (rifampin or ciprofloxacin or single-dose ceftriaxone for meningococcal household contacts; rifampin for Hib contacts < 4 yr unvaccinated household per AAP Red Book + CDC); antiseizure medication taper plan if seizure at presentation; speech therapy if developmental regression; mental-health screen for child + caregivers (post-PICU PTSD / depression common); IDSA 2004 Tunkel + NICE NG240 (2024) + AAP Red Book + Cochrane Brouwer 2010

Disposition criteria:
- Resolution: audiology completed + vaccinations administered + antiseizure plan stable + neurodev trajectory on track + no late complications at 12 months — discharge from meningitis-specific surveillance back to standard primary peds care (IDSA 2004 Tunkel; NICE NG240 2024; AAP Red Book)

Escalation triggers (move to higher acuity):
- New fever / chills / new headache or neck stiffness / fontanelle bulging in infant → ED for recurrent-meningitis workup (IDSA 2004 Tunkel; AAP Red Book)
- New focal neurologic deficit / new seizure / worsening cognition → urgent peds-neurology + imaging (IDSA 2004 Tunkel; ESCMID 2016)
- Subacute headache + nausea / vomiting / cognitive decline → suspect late-onset hydrocephalus → urgent imaging + peds-neurosurgery (ESCMID 2016)
- Audiology demonstrates moderate-severe sensorineural hearing loss → ENT + hearing-aid / cochlear-implant evaluation (Cochrane Brouwer 2010; NICE NG240 2024)
- Developmental regression on neurodev assessment → peds-developmental clinic + speech therapy + OT/PT + school accommodations (AAP Red Book)
- PHQ-9-A ≥ 15 OR suicidal ideation in adolescent OR UCLA-PTSD-RI elevated in younger child → mental-health urgent referral
- Caregiver PHQ-9 ≥ 15 OR PSS-FH elevated → caregiver mental-health referral + PICS-Family support
- Close contact (meningococcal aetiology) develops fever / rash / headache → ED for immediate evaluation (CDC meningococcal guidelines; NICE NG240 2024)
- Recurrent meningitis episode → admit + workup for predisposition (complement deficiency, anatomic CSF leak, dermal sinus, immunodeficiency) (IDSA 2004 Tunkel; AAP Red Book)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Petechial / purpuric rash with fever ± shock (suspected meningococcaemia)
- [LIFE_THREATENING] Cushing triad (HTN + bradycardia + irregular respirations), papilledema, fixed/dilated pupil, or rapid GCS decline
- [LIFE_THREATENING] Continuous or recurrent seizure ≥5 min in a child with suspected meningitis

Citations

- IDSA 2004 Bacterial Meningitis (Tunkel) + IDSA 2024 community-acquired BM update (referenced; PMID pending) + IDSA/AAN 2017 healthcare-associated ventriculitis & meningitis + AAP Red Book current edition + Cochrane Brouwer 2010 corticosteroids in bacterial meningitis (de Gans / van de Beek) + ESCMID 2016 + NICE NG240 2024 + Nigrovic Bacterial Meningitis Score (JAMA 2007) + SSC peds 2020 (Weiss) for meningitis-with-shock overlap + PALS 2020/2024 [PMID:15494903](https://pubmed.ncbi.nlm.nih.gov/15494903/)
- Cited evidence (PMID 15509818) [PMID:15509818](https://pubmed.ncbi.nlm.nih.gov/15509818/)
- Cited evidence (PMID 21612470) [PMID:21612470](https://pubmed.ncbi.nlm.nih.gov/21612470/)
- Cited evidence (PMID 17200475) [PMID:17200475](https://pubmed.ncbi.nlm.nih.gov/17200475/)
- Cited evidence (PMID 12432041) [PMID:12432041](https://pubmed.ncbi.nlm.nih.gov/12432041/)

Last reconciled with current guidelines: 2026-05-22.
References
  • IDSA 2004 Bacterial Meningitis (Tunkel) + IDSA 2024 community-acquired BM update (referenced; PMID pending) + IDSA/AAN 2017 healthcare-associated ventriculitis & meningitis + AAP Red Book current edition + Cochrane Brouwer 2010 corticosteroids in bacterial meningitis (de Gans / van de Beek) + ESCMID 2016 + NICE NG240 2024 + Nigrovic Bacterial Meningitis Score (JAMA 2007) + SSC peds 2020 (Weiss) for meningitis-with-shock overlap + PALS 2020/2024 — PMID:15494903
  • Cited evidence (PMID 15509818) — PMID:15509818
  • Cited evidence (PMID 21612470) — PMID:21612470
  • Cited evidence (PMID 17200475) — PMID:17200475
  • Cited evidence (PMID 12432041) — PMID:12432041